| Similar Articles |
|---|
 |
The Motley Fool
September 5, 2006
Brian Gorman |
Bayer Rising? Bayer still has some hoops to jump through before it's in tip-top shape, but the company has some tantalizing opportunities. Investors, it's not too early to put the German conglomerate on the watch list.   |
Reason
February 2007
Ronald Bailey |
Snap, Crackle, Poison? G.M. rice scare -- The rice flap isn't deadly, but it does demonstrate a need for reform in the inefficient way genetically enhanced crop varieties are approved internationally. |
The Motley Fool
November 30, 2006
Brian Lawler |
Not Bad, Bayer The company's buyout of fellow German firm Schering AG looks like a boon to its bottom line. Investors, take note. |
The Motley Fool
April 2, 2004
Brian Gorman |
Bayer's Food Fight Bayer's recent U.K. troubles reflect Europe's continued distaste for genetically modified foods. |
The Motley Fool
March 27, 2006
Rich Smith |
Bayer Prescribes Itself a Buyout Bayer's bid for Schering trumped an earlier $17.5 billion offer from yet another German powerhouse, Merck KGaA. Why would Bayer pay so much for Schering? Investors, take note. |
The Motley Fool
November 29, 2004
Brian Gorman |
Glass Half Full for Bayer Bayer is battling drug recall demons, but the company's positives seem to outweigh its negatives. The German drug and chemical giant posted a net profit of $42 million, reversing a massive loss recorded in the same period last year. |
IndustryWeek
September 1, 2002
John S. McClenahen |
Bayer's Formula: Two Sites Both Research Triangle Park, N.C., and Kansas City, Mo., are home to newly created Bayer CropScience's North American Operations. |
The Motley Fool
July 20, 2004
Brian Gorman |
Bayer Reshuffles Business Bayer, one of Germany's most venerable industrial names, is revamping its house. Seemingly in one fell swoop, the company is spinning off its Lanxess chemicals and polymers unit and buying Roche's over-the-counter-drugs business. |
BusinessWeek
June 23, 2011
Naomi Kresge |
Bayer Aspirin Is Feeling Plenty Healthy While J&J's Tylenol recovers from a recall, sales of century-old Bayer are soaring. |
The Motley Fool
March 3, 2005
Brian Gorman |
Bayer Heals Itself The latest earnings report suggests things are looking up -- and drug development may soon yield more good news for investors. |
The Motley Fool
May 28, 2008
Brian Lawler |
A Strange Novartis MS Drug Story Novartis gets approval for a drug with an interesting history. |
Pharmaceutical Executive
November 1, 2006
Patrick Clinton |
Man in a Hurry Bureaucratic? Bayer? Not if you ask Arthur Higgins. In just over two years, the head of Bayer HealthCare has proved that pharma can be a quick and nimble business. |
The Motley Fool
May 19, 2004
Brian Gorman |
U.N. Plants Seed for Agribusiness Its endorsement of biotech foods could clear the way for agribusiness in the developing world. |
Chemistry World
September 23, 2014
Andy Extance |
Bayer to sever polymer arm The German chemical giant has announced plans to spin off its MaterialScience business as a new company within 12 -- 18 months. |
The Motley Fool
October 16, 2006
Brian Lawler |
Bayer's Big Drug Boo-Boo The company's forgetfulness could end up hurting its reputation even worse than its revenues. |
Chemistry World
July 5, 2012 |
Bayer buys crop protection firm for $425m German chemical and healthcare giant Bayer has struck a deal to buy US firm AgraQuest, which makes pest control products based on 'natural' or specially bred microorganisms. |
The Motley Fool
March 2, 2005
Brian Gorman |
Monsanto's Brazil Benefit Brazil is on the cusp of legalizing genetically modified seed sales, a potential boon for Monsanto. |
The Motley Fool
August 7, 2007
Brian Lawler |
Nektar Makes a Deal Nektar Therapeutics signs a deal with Bayer AG in an effort to move itself closer to profitability. In return, Bayer gets a co-promotion profit-sharing deal in the U.S., and commercialization rights elsewhere. |
BusinessWeek
October 13, 2003
Gene G. Marcial |
Sontra Medical Looks Healthier with Bayer With giant Bayer as a partner, tiny Sontra Medical could make it big in the $5 billion market for home glucose testing for diabetics. |
The Motley Fool
March 5, 2008
Brian Orelli |
Yasmin Raises the Revenue Barr Barr gets a patent on Bayer's Yasmin overturned. |
Chemistry World
November 16, 2012
Andrew Turley |
What lies within Bayer is looking to 'modestly' increase its R&D budget next year -- it was 3 billion euros( 2.4 billion pounds) for 2012 -- and place new emphasis on transferring ideas between research areas within the company. |
BusinessWeek
August 1, 2005 |
The Side Effects of Drugged Crops The Union of Concerned Scientists' Margaret Mellon explains the group's concerns about the dangers genetically altered food poses. |
Chemistry World
September 2, 2009
Helen Carmichael |
Bayer bows to safety concerns One year after an explosion that led to two fatalities, Bayer CropScience is to eliminate 80 per cent of its methyl isocyanate stockpile at its Institute, West Virginia site. |
Chemistry World
September 18, 2012
Andrew Turley |
Bayer $145 million animal health deal Bayer has signed a $145 million deal to buy the US part of the animal health business at Israeli generics giant Teva. |
Food Processing
April 2013
Rory Gillespie |
Fear and Loathing Haunt GMOs It's difficult to balance the lack of negative scientific evidence against consumers' right to know what's in their food. |
The Motley Fool
August 17, 2009
Brian Orelli |
Preparing for a Home Run Some good news and bad news for companies selling drugs to treat multiple sclerosis, after Novartis announces Extavia has been approved by the FDA. |
Chemistry World
July 22, 2013
Phillip Broadwith |
Monsanto abandons GM crops in Europe The company will focus on conventional breeding to develop new crop varieties in the EU, and develop biotech crops in regions where they are more accepted, such as North America. |
Chemistry World
October 5, 2012
Phhillip Broadwith |
Bayer and Evotec team up on endometriosis Bayer Healthcare and Evotec have agreed to collaborate in their search for drugs for endometriosis, a disease in which cells of the type that normally line the uterus wall grow outside of the womb. |
The Motley Fool
June 25, 2008
Brian Orelli |
An Even More Complicated Patent Settlement Barr and Bayer settle their dispute about Yasmin. That's as simple as it gets. |
BusinessWeek
March 13, 2006
Gene G. Marcial |
How Syngenta's Garden Grows Although it is a big global player in seeds and crop protection, Switzerland's $16 billion market cap Syngenta it gets scant attention on the Street. |
Chemistry World
June 22, 2007
Ned Stafford |
Big Pharma Not Interested in 'Male Pill' German drug giant Bayer has officially stopped research and development of a hormonal male contraceptive, yet another sign that the pharma industry has lost interest in developing the so-called 'male pill.' |
Chemistry World
January 10, 2013
Laura Howes |
Golden rice trial breached ethical guidelines Golden rice, the -carotene boosted genetically modified rice, which it is hoped will help to prevent cases of childhood blindness, has suffered another setback. Chinese researchers were judged to have breached ethical guidelines when they ran a trial in which children were fed the GM rice. |
The Motley Fool
September 6, 2006
Selena Maranjian |
The Price of Rice: Who Knew? The rapidly developing economies in Asia mean fewer rice paddies. If you're an investor in a company that uses a lot of rice, you may want to pay attention to this issue. |
Chemistry World
May 9, 2014
Andy Extance |
Bayer wins race to buy Merck & Co consumer care Germany's Bayer has won a bidding contest for US giant Merck & Co's consumer care business unit, seemingly thanks to a heart drug collaboration sweetener. |
Chemistry World
January 18, 2013
Ned Stafford |
EU food agency links pesticides to bee decline Chemical giants Bayer CropScience and Syngenta are both disputing the conclusions of a report from the European Food Safety Authority that says that bees might be at risk from neonicotinoid insecticides produced by the two companies. |
